Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area

Allon Kahn, Elizabeth J. Carey, Janis E. Blair – 6 December 2014 – Recipients of liver transplantation (LT) are at increased risk for symptomatic coccidioidomycosis, primarily because of chronic immunosuppression and impaired cellular immunity. Unfortunately, no consensus exists regarding optimal posttransplant prophylaxis. In a prior study at our institution, we observed both de novo and recurrent coccidioidomycosis despite targeted antifungal prophylaxis.

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

Rohit Loomba, Claude B. Sirlin, Brandon Ang, Ricki Bettencourt, Rashmi Jain, Joanie Salotti, Linda Soaft, Jonathan Hooker, Yuko Kono, Archana Bhatt, Laura Hernandez, Phirum Nguyen, Mazen Noureddin, William Haufe, Catherine Hooker, Meng Yin, Richard Ehman, Grace Y. Lin, Mark A. Valasek, David A. Brenner, Lisa Richards, San Diego Integrated NAFLD Research Consortium (SINC) – 6 December 2014 – Ezetimibe inhibits intestinal cholesterol absorption and lowers low‐density lipoprotein cholesterol.

Subscribe to